Sanofi slumps on loss of Lantus lawsuit

The US Patent and Trademark Appeal Board (PTAB) has ruled in favor of Netherlands-based drugmaker Mylan (Nasdaq: MYL) as it invalidated Sanofi’s (Euronext: SAN) Lantus (insulin glargine 100 Units/mL) formulation patents.

Sanofi sells Lantus, a long-acting insulin used to treat diabetes, in vials (Lantus) and as a disposable injection pen (Lantus SoloSTAR). Combined sales of these two products earned the French pharma major around $6.5 billion in the 12 months ending October 31.

Mylan’s application to market generic versions of Lantus and Lantus SoloSTAR, co-developed with Indian company Biocon (BSE: 532523), is under active review by the US Food and Drug Administration.